Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS101 Latanoprost Insert vs Topical Latanoprost in Glaucoma/OHT
NCT02129673Phase 2Completed
- Sponsor
- ViSci Ltd.
- Start
- May 2014
- Primary completion
- May 2017
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of VS101 in open-angle glaucoma (OAG), ocular hypertension, sponsored by ViSci Ltd.. Started May 2014; status: completed.
02
Drugs
VS101
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02129673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129673.